(Q30305461)

16 June 2017

1 reference

title

Influenza virus neuraminidase inhibitors (English)

1 reference

16 June 2017

1 reference

L V Gubareva

1

1 reference

16 June 2017

L Kaiser

series ordinal

2

1 reference

16 June 2017

F G Hayden

series ordinal

3

1 reference

16 June 2017

language of work or name

English

0 references

publication date

1 March 2000

1 reference

16 June 2017

1 reference

16 June 2017

355

1 reference

16 June 2017

827-835

1 reference

16 June 2017

9206

1 reference

Rational design of potent sialidase-based inhibitors of influenza virus replication

16 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

New approaches to influenza chemotherapy. Neuraminidase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Neuraminidase inhibitors as anti-influenza virus agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Disarming flu viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Characterization of influenza A/HongKong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Influenza virus resistance to neuraminidase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

A single sequence change destabilizes the influenza virus neuraminidase tetramer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Zanamivir: a review of clinical safety

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

The low potential for drug interactions with zanamivir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

A novel mechanism for the acquisition of virulence by a human influenza A virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2911433-8

7 January 2021

10.1016/S0140-6736(99)11433-8

Identifiers

DOI

1 reference

16 June 2017

1 reference